Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03975387 · ClinicalTrials.gov registry record · Phase 1
Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53
A Phase 1 study, sponsored by Taiho Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
NCT03975387 is a Phase 1 study that was terminated before completion, run by Taiho Oncology. The registered enrollment target is 106 participants.
The verdict
NCT03975387, a Phase 1 study, was terminated before completion, sponsored by Taiho Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
Study Summary
Study ASTX295-01 is a first in human Phase 1/2 open-label study of the safety, pharmacokinetics, and preliminary activity of ASTX295 in participants with wild-type TP53 advanced solid tumors. Phase 1 is a dose escalation and dose expansion study design. Sponsor made the strategic decision to not pursue the Phase 2 part of the study.
Interventions
- DRUG ASTX295
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2019-07-11 |
| Est. Completion | 2024-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03975387
The ClinicalTrials.gov registry entry for NCT03975387 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ASTX295 is the first listed.
NCT03975387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03975387 about?
NCT03975387 is a clinical study titled "Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53". Study ASTX295-01 is a first in human Phase 1/2 open-label study of the safety, pharmacokinetics, and preliminary activity of ASTX295 in participants with wild-type TP53 advanced solid tumors. Phase 1 is a dose escalation and dose expansion study design. Sponsor made the strategic decision to not pur...
What is the current status of trial NCT03975387?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2019-07-11. Estimated completion is 2024-08-15.
What interventions are being tested in trial NCT03975387?
The interventions under investigation include: ASTX295 (DRUG).
Who is sponsoring clinical trial NCT03975387?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.